Cargando…

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial

BACKGROUND: Mesothelioma is an incurable, apoptosis-resistant cancer caused in most cases by previous exposure to asbestos and is increasing in incidence. It represents a growing health burden but remains under-researched, with limited treatment options. Early promising signals of activity relating...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fennell, Dean A., Kirkpatrick, Emma, Cozens, Kelly, Nye, Mavis, Lester, Jason, Hanna, Gerard, Steele, Nicola, Szlosarek, Peter, Danson, Sarah, Lord, Joanne, Ottensmeier, Christian, Barnes, Daniel, Hill, Stephanie, Kalevras, Mihalis, Maishman, Tom, Griffiths, Gareth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907297/ https://www.ncbi.nlm.nih.gov/pubmed/29669604 http://dx.doi.org/10.1186/s13063-018-2602-y

Ejemplares similares

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
por: Fennell, Dean A, et al.
Publicado: (2021)

Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial
por: Fennell, Dean A., et al.
Publicado: (2022)

Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres
por: Fennell, Dean, et al.
Publicado: (2023)

SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial
por: Crabb, Simon, et al.
Publicado: (2018)

Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial
por: Fennell, Dean A., et al.
Publicado: (2022)

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
por: Dudek, Arkadiusz Z., et al.
Publicado: (2023)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
por: Smyth, Elizabeth, et al.
Publicado: (2022)

JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
por: Miyamoto, Yosuke, et al.
Publicado: (2021)

Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2020)

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series
por: Hashimoto, Kentaro, et al.
Publicado: (2022)

Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial
por: Hanna, Glenn J., et al.
Publicado: (2023)

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023)

Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
por: Phillips, Melissa M., et al.
Publicado: (2023)

MENOS4 trial: a multicentre randomised controlled trial (RCT) of a breast care nurse delivered cognitive behavioural therapy (CBT) intervention to reduce the impact of hot flushes in women with breast cancer: Study Protocol
por: Fenlon, Deborah, et al.
Publicado: (2018)

Evaluating the effect of immune cells on the outcome of patients with mesothelioma
por: Chee, Serena J, et al.
Publicado: (2017)

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss
por: Crabb, Simon J., et al.
Publicado: (2017)

Adherence to transfusion strategies in a randomized controlled trial: experiences from the TITRe2 trial
por: Pike, Katie, et al.
Publicado: (2016)

Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma
por: Kefas, Joanna, et al.
Publicado: (2022)

Patient experiences of participation in a radical thoracic surgical trial: findings from the Mesothelioma and Radical Surgery Trial 2 (MARS 2)
por: Warnock, Clare, et al.
Publicado: (2019)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

Precision Therapy for Mesothelioma: Feasibility and New Opportunities
por: Dulloo, Sean, et al.
Publicado: (2021)

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
por: Muers, Martin F, et al.
Publicado: (2008)

Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials
por: Mankor, Joanne M., et al.
Publicado: (2020)

Mesothelioma: Hippo pathway as a target, lessons from COMMAND
por: Fennell, Dean A., et al.
Publicado: (2019)

Effectiveness of nurse‐led group CBT for hot flushes and night sweats in women with breast cancer: Results of the MENOS4 randomised controlled trial
por: Fenlon, Deborah, et al.
Publicado: (2020)

Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial
por: de Fonseka, Duneesha, et al.
Publicado: (2018)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes
por: Jones, Riley G., et al.
Publicado: (2018)

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Yoneda, Hiroto, et al.
Publicado: (2021)

Abdominal pain as an initial symptom of isolated ACTH deficiency induced by nivolumab in a patient with malignant mesothelioma
por: Hata, Koichi, et al.
Publicado: (2021)

A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic
por: Church, Matt, et al.
Publicado: (2021)

The OMACS-PIL study: a randomised controlled trial within the OMACS observational study
por: Culliford, Lucy, et al.
Publicado: (2019)

Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program
por: Cantini, Luca, et al.
Publicado: (2020)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
por: Ye, Zhuo-miao, et al.
Publicado: (2022)

Ultrasound confirmation of guidewire position may eliminate accidental arterial dilatation during central venous cannulation
por: Gillman, Lawrence M, et al.
Publicado: (2010)

Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
por: Karydis, Ioannis, et al.
Publicado: (2016)

Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report
por: Takami, Tomoya, et al.
Publicado: (2021)

BTS guideline for the investigation and management of malignant pleural mesothelioma
por: Woolhouse, Ian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_55acflto5sa52ln6lr0p1pso7c